After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
We have now added a new section called the "Assay History List" to the "At A Gla...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...